Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: A meta-analysis

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 51, Issue 2, 2011, Pages 158-165

  Cabrera, Yasmina ^a,c   FernÚndez Guisasola, Jaime ^b   Lobo, Paloma ^a   GÚmir, Susana ^a   Úlvarez, Julio ^a  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b International Ruber Hospital   (Spain)

^c NONE   (Spain)

Author keywords

mid trimester abortion; misoprostol; sublingual administration; vaginal administration

Indexed keywords

MISOPROSTOL; OXYTOCIN;

ARTICLE; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; HUMAN; META ANALYSIS; MULTIPARA; NAUSEA; NULLIPARA; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PREGNANCY TERMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; VOMITING;

ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, SUBLINGUAL; ADULT; FEMALE; HUMANS; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, SECOND; TREATMENT OUTCOME;

EID: 79953804483     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2010.01264.x     Document Type: Article

References (34)

1. Ngai SW, Tang OS, Ho PC,. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract Res Clin Obstet Gynaecol 2003; 17: 765-775. (Pubitemid 37168293)
2. World Health Organization. Medical Methods for Termination of Pregnancy: Report of a Who Scientific Group. Who Technical Report Series No. 871. Geneva: World Health Organization, 1997. ISBN 92-4-120871-6. OCLC 38276325.
3. Tietza C,. Second-trimester abortion: a global view. In:, Berger GS, Berger WE, Keith LG, eds. Second-Trimester Abortion. Boston: John Wright, 1981; 1-11.
4. Gõmez Ponce de Leõn R, Wing DA,. Misoprostol for termination of pregnancy with intrauterine fetal demise in the second and third trimester of pregnancy-a systematic review. Contraception 2009; 79: 259-271.
5. Lalitkumar S, Bygdeman M, Gemzell-Danielsson K,. Mid-trimester induced abortion: a review. Hum Reprod Update 2007; 13: 37-52. (Pubitemid 44932823)
6. Royal College of Obstetricians and Gynaecologists, editors. Medical methods of abortion. The Care of Women requesting Induced Abortion. Evidence-Based Clinical Guideline Number 7. London: RCOG Press, 2004; 52-56.
7. El-Refaey H, Hinshaw K, Templeton AA,. The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). Hum Reprod 1993; 8: 1744-1746. (Pubitemid 23299803)
8. Dickinson JE, Godfrey M, Evans SF,. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: a randomized controlled trial. J Matern Fetal Med 1998; 7: 115-119.
9. Dodd JM, Crowther CA,. Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death (Protocol). Cochrane Database Syst Rev 2004; (3): Art No.: CD004901. DOI:.
10. Caliskan E, Dilbaz S, Doger E, et al. Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation. J Reprod Med 2005; 50: 173-180. (Pubitemid 40393258)
11. Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90: 88-92. (Pubitemid 27272963)
12. Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17: 332-336. (Pubitemid 34168436)
13. Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet Gynecol 2006; 108: 582-590. (Pubitemid 44337099)
14. Ho PC, Ngai SW, Liu KL, et al. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol 1997; 90: 735-738.
15. Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol 2002; 187: 853-857. (Pubitemid 35178369)
16. Akoury HA, Hannah ME, Chitayat D, et al. Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation. Am J Obstet Gynecol 2004; 190: 755-762. (Pubitemid 38406789)
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 2009; 6 (6): e1000097. DOI:.
19. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
20. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
21. Tang OS, Lau WN, Chan CC, Ho PC,. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111: 1001-1005. (Pubitemid 39223052)
22. Elhassan EM, Abubaker MS, Adam I,. Sublingual compared with oral and vaginal misoprostol for termination of pregnancy with second-trimester fetal demise. Int J Gynaecol Obstet 2008; 100: 82-83. (Pubitemid 350216885)
23. Bhattacharjee N, Saha SP, Ghoshroy SC, et al. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 2008; 48: 165-171. (Pubitemid 351441607)
24. von Hertzen H, Piaggio G, Wojdyla D, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009; 24: 106-112.
25. Karsidag AY, Buyukbayrak EE, Kars B, et al. Vaginal versus sublingual misoprostol for second-trimester pregnancy termination and effect on Doppler measurements. Int J Gynaecol Obstet 2009; 106: 250-253.
26. Tang OS, Schweer H, Lee SW, Ho PC,. Pharmacokinetics of repeated doses of misoprostol. Hum Reprod 2009; 24: 1862-1869.
27. Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000; 95: 403-406. (Pubitemid 30100507)
28. Tang OS, Gemzell-Danielsson K, Ho PC,. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007; 99 (Suppl 2): S160-S167. (Pubitemid 350101541)
29. Dickinson JE, Evans SF,. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002; 186: 470-474. (Pubitemid 34234159)
30. Fawzy M, Abdel-Hady el-S,. Midtrimester abortion using vaginal misoprostol for women with three or more prior cesarean deliveries. Int J Gynaecol Obstet 2010; 110: 50-52.
31. Varras M, Akrivis Ch,. Misoprostol for second trimester abortion in women with prior uterine incisions. Clin Exp Obstet Gynecol 2010; 37: 10-12.
32. Borenstein N, Hedges LV,. Fixed-effect versus random-effects models. In:, Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, eds. Introduction to Meta-Analysis. Chichester, West Sussex, UK: John Wiley & Sons, 2009; 77-86.
33. Pandit JJ,. Editorial: meta-analysis of the effects of dopexamine in major surgery: do all roads lead to Rome? Anaesthesia 2009; 64: 585-588.
34. Trikalinos TA, Ioannidis JP,. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 2001; 54: 245-252. (Pubitemid 32153868)